Treatments for Age-Related Macular Degeneration: Going Head to Head

Date: May 1st, 2011

Exciting treatments make slowing and even restoring vision loss in wet age-related macular degeneration (wAMD) patients a reality. Two of the most frequently used treatments are currently in the spotlight as they go head-to-head in clinical trials comparing their effectiveness, and to some extent, exploring their costs. The Anti-VEGF Treatments AMD is the leading cause of irreversible vision loss in Americans age 60 and over. This progressive eye disease involves the breakdown of the macula—the light-sensing portion of the retina—resulting in the

Empowering Patients with Information and Improving Care

Date: March 1st, 2008

No one can deny that our country’s health care spending is reaching an unmanageable level. In 2006 we spent over $2 trillion on health care and some experts predict that we’ll be spending twice that much by 2017. While you might assume that population growth is causing these increases—more people usually means more health care—we’re also seeing a rise in the amount of money that we spend on each person. One of the major reasons that health care costs are skyrocketing